主页 > 医学新闻 >
【drug-news】研究称，Naproxen止痛药不会引发心脏病
Sat Nov 11, 2006 5:32pm ET
By Maggie Fox, Health and Science Editor
WASHINGTON (Reuters) - Naproxen, a common, over-the-counter pain reliever used for arthritis and other aches and pains, appears to be safe for the heart, despite warnings, researchers reported on Saturday.
A study of 41 healthy men and women showed naproxen, sold under the brand name Aleve by Bayer Consumer Care, "thins" the blood in much the same way as aspirin does.
This anti-clotting effect is seen on platelets, which are structures in the blood that help make clots.
Dr. Michael Schiff of the Denver Arthritis Clinic and Dr. Marc Hochberg of the University of Maryland School of Medicine studied the blood of the 41 volunteers when they took Aleve once or twice a day for a week, compared to a placebo and then compared to 81 mg low-dose aspirin.
The prescription dose of naproxen had already been shown to reduce platelet activity but this was the first test with over-the-counter doses.
The researchers measured a compound in the blood called serum thromboxane B2 and found that naproxen had similar effects to that of coated aspirin.
"This is good news. It is reassuring news," Schiff said in a telephone interview.
"These data, confirming that the over-the-counter dose of naproxen sodium has a measurable antiplatelet effect, add to the body of evidence about the safety of this compound," added Hochberg.
Naproxen is in a class of drugs called non-steroidal anti-inflammatory drugs, or NSAIDS.
In 2004, the Food and Drug Administration asked the makers of ibuprofen, naproxen and ketoprofen to add labeling with more warnings about gastrointestinal and heart risks of the drugs, and advising patients to take them only for a limited time.
This came after some of a new class of drugs called COX-2 inhibitors were found to greatly raise the risk of heart attacks and strokes.
The COX-2 inhibitors were ironically designed to be safer alternatives to aspirin, ibuprofen and other NSAIDs, which can cause sometimes fatal stomach bleeding.
Merck and Co. withdrew its arthritis drug Vioxx from the market in September 2004. It is facing more than 11,500 product liability lawsuits from people claiming to have been harmed by Vioxx.
Other studies then suggested naproxen might also be dangerous, although many experts have questioned this.
"We know from very large epidemiological (population) studies and all sorts of studies that naproxen is a safe drug, perhaps the best of the NSAIDS," said Dr. Steve Nissen of the Cleveland Clinic Foundation.
Nissen is currently testing 21,000 patients to compare the safety of naproxen, aspirin and another COX-2 inhibitor, Pfizer's Celebrex, known generically as celecoxib.
http://today.reuters.com/news/articlenews.aspx?type=healthNews&storyID=2006-11-11T223207Z_01_N11414450_RTRUKOC_0_US-NAPROXEN.xml&WTmodLoc=NewsArt-L3-Health+NewsNews-2 历史新闻：
又一止痛药亮红灯！Naproxen增加心脏病发率50%
--------------------------------------------------------------------------------
2004年12月22日 02:51 香港商报
【商报综合外电报道】继美国辉瑞药厂的止痛药Celebrex会增加心脏病发的严重副作用后，美国食品药物管理局（FDA）20日对同类的另一款非处方止痛药Naproxen提出警告，因其亦有类似的副作用。由于Naproxen与Celebrex同属Cox-2抑制剂，这类药品的使用安全性已经备受质疑。FDA是根据美国国家卫生研究院对某些非类固醇止痛药对抑制痴呆症效果的临床实验成果发出警告。实验发现，服用Naproxen止痛药的患者，促发心血管疾病的几率高50%。FDA官员克威德博士说，国卫院的研究是首次显示出Naproxen有可能增加心脏病或者中风几率的研究。FDA警告，患者不应该服用超过医师建议的剂量，也不要连续服用超过十天，除非有医师指示。Naproxen是学名，许多药厂都有生产这种非类固醇止痛消炎药，例如Napton，拜尔的Aleve以及罗氏药厂的Naprosyn，原本列为处方药，后改为不需医师处方即可自行在药局购买服用，在美国从1976年核准上市至今已经将近30年，在治疗关节炎等方面广为使用。
Naproxen暂无使用新规
美国国卫院的这项实验，研究的药物包括Celebrex和Naproxen，在相继发现这两种药品的严重副作用后，国卫院已经在20日宣布中止研究。研究从2001年起针对2625名患者进行临床实验，原定进行七年长期追踪。在这项研究领导人之一，同时也是华盛顿大学老人病学研究负责人布莱特纳说，国卫院的研究初步资料显示，受试者中有70人发生中风和心脏病，其中23人因此死亡，但是在服用Naproxen那组人中，这个比率高了50%。Celebrex和Naproxen都列为Cox-2抑制剂，这两种药品接连出问题，让FDA不得不思考对这类药品定出新规范。FDA将仔细评估研究的发现，但是至少未来几天内不会针对Naproxen定出新的使用规范。 [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-05-29 05:11
医学,生命科学网